Andersen J, Poulsen H S
Department of Experimental Clinical Oncology, Aarhus Kommunehospital, Denmark.
Acta Oncol. 1988;27(6A):761-5. doi: 10.3109/02841868809091782.
Treatment of metastatic breast cancer based on the estrogen receptor content (ER) of the primary tumor builds on the assumption that the ER status of the primary tumor and the metastases are largely equal. Studies addressing this question have used ligand-binding assays for ER determination and have consequently been subject to the limitations of this technique. Reported disparity rates have been 20%. In order to avoid some of these limitations, we used an immunohistochemical assay in paraffin-embedded tissue. Among a total of 92 examined regional lymph node metastases, ER status was equal with that of their 37 primaries in 84 cases (91%). Semiquantified ER content was significantly correlated in primary tumor and the metastases (r = 0.67, p less than 0.001). Among a total of 51 distant metastases, equal ER status was found in 44 (86%) cases and a quantitative relationship could not be established. Disparities can be due to methodological errors in the histochemical assay or tumor heterogeneity.
基于原发肿瘤雌激素受体含量(ER)对转移性乳腺癌进行治疗,其依据的假设是原发肿瘤和转移灶的ER状态基本相同。针对这一问题的研究采用配体结合分析法来测定ER,因此受到该技术局限性的影响。报道的差异率为20%。为避免其中一些局限性,我们在石蜡包埋组织中采用了免疫组织化学分析法。在总共92个检测的区域淋巴结转移灶中,84例(91%)的ER状态与其37个原发灶相同。原发肿瘤和转移灶中ER含量的半定量结果显著相关(r = 0.67,p < 0.001)。在总共51个远处转移灶中,44例(86%)的ER状态相同,且无法建立定量关系。差异可能是由于组织化学分析中的方法学误差或肿瘤异质性所致。